Papers/PMID:41006034
Antitumor Potential of Epigallocatechin Gallate in Overcoming Molecular Therapy Resistance in Hepatocellular Carcinoma.
Anticancer research2025The record
1 finding · 1 compound · 1 endpoint
What it reported
How to read these marksWhat moved
1 finding
(-)-epigallocatechin 3-gallate — inhibits EGFR
SpeculativeGrade F, Speculative. Mechanistic inference, no evidence found, or evidence weakened below D.Finding“EGCG also suppressed EGFR expression, especially in Hep3BLR.”
Quoted verbatim from Antitumor Potential of Epigallocatechin Gallate in Overcoming Molecular Therapy Resistance in Hepatocellular Carcinoma.. - Study
- in vitro · not in humans
- Dose
- 10 μg/ml
- Population
- Hep3B human hepatocellular carcinoma cells and the lenvatinib-resistant Hep3BLR subline
Antitumor Potential of Epigallocatechin Gallate in Overcoming Molecular Therapy Resistance in Hepatocellular Carcinoma.2025PMID:41006034Permalink